Results 51 to 60 of about 5,144 (141)

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Real‐World Treatment Patterns, Clinical Outcomes, and Symptom Burden in Patients With Psoriatic Arthritis Prescribed Ixekizumab in the United States

ACR Open Rheumatology
Objective The objective of this study was to describe the real‐world characteristics and clinical status of patients with psoriatic arthritis (PsA) currently prescribed ixekizumab.
Sherry Rohekar, Aisha Vadhariya, Sarah Ross, William Malatestinic, Boris Janos, Nicola Massey, Megan Hughes, Sarah Weatherby, Julie Birt, Anthony Sebba   +9 more
doaj   +1 more source

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain

BMJ Open, 2020
Objective To conduct a cost-effectiveness analysis from the perspective of the Spanish National Health System (NHS) comparing ixekizumab versus secukinumab.Design A Markov model with a lifetime horizon and monthly cycles was developed based on the York ...
Susanne Hartz, Christophe Sapin, Bernd Schweikert, Chiara Malmberg, Mercedes Núñez, Tatiana Dilla   +5 more
doaj   +1 more source

Superior Clinical and Economic Value of IL‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

International Journal of Dermatology, Volume 65, Issue 11, Page 2362-2370, November 2026.
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco, Elena Ippoliti, Niccolò Gori, Giacomo Caldarola, Clara De Simone, Nicoletta Di Giorgi, Paulo Gabriel Longo, Marco Galluzzo, Luca Bianchi, Lorenzo Marcelli, Marina Talamonti, Maria Vittoria Cannizzaro, Lucia Di Nardo, Ketty Peris   +13 more
wiley   +1 more source

Building a Framework for Sexual and Reproductive Health Care in the Rheumatology Context: Content and Approaches

Arthritis Care &Research, Volume 78, Issue 10, Page 1510-1521, October 2026.
People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley   +1 more source

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

Arthritis &Rheumatology, Volume 78, Issue 10, Page 2089-2101, October 2026.
Objective Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Joseph F. Merola, Philip Mease, Alan Kivitz, Naveed Sattar, Laura C. Coates, Daniel Aletaha, Cynthia E. Kartman, Peter Fischer, Luna Sun, Píndaro Martínez‐Osuna, Andris Kronbergs, Purvi Prajapati, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie   +14 more
wiley   +1 more source

Assessment of Major Adverse Cardiovascular Event Across Diverse Racial Groups of Psoriasis Patients on Biologic Therapy: A Retrospective Cohort Study

The Journal of Dermatology, Volume 53, Issue 10, Page 1439-1447, October 2026.
ABSTRACT Psoriasis is associated with an increased risk of major adverse cardiovascular events (MACE), and biologic therapy may reduce this risk by targeting systemic inflammation. However, limited data exist on whether long term MACE risk differs by biologic class or across racial groups. We conducted a retrospective cohort study to assess the risk of
Chunghwan Ro, Ana Ormaza Vera, Waleed Adawi, Clinton W. Enos   +3 more
wiley   +1 more source

Ixekizumab for psoriasis [PDF]

The Lancet, 2016
Kenji, Tsuda, Tetsuya, Tanimoto, Seiji, Takenouchi, Saori, Sakaue, Tsunehiko, Komatsu   +4 more
openaire   +2 more sources

Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)

Dermatology and Therapy
Introduction The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safety in both ...
Mario Valenti, Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Paolo Dapavo, Valentina Dini, Francesca M. Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Diego Orsini, Massimo Travaglini, Antonio Costanzo, Alessandra Narcisi   +22 more
doaj   +1 more source

IL-17A Inhibitor Switching – Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience

Acta Dermato-Venereologica, 2019
Interleukin-17A inhibitors are a promising alternative to tumor necrosis factor-α inhibitors for the treatment of psoriasis. In-class switch has been hardly investigated for interleukin-17A inhibitors.
Shany Sherman, Efrat Solomon Cohen, Iris Amitay-Laish, Emmilia Hodak, Lev Pavlovsky   +4 more
doaj   +1 more source